An Open-label Study of ALTO-100 in Adults With Major Depressive Disorder and/or Post-traumatic Stress Disorder
Latest Information Update: 13 May 2024
At a glance
- Drugs ALTO-100 (Primary)
- Indications Major depressive disorder; Post-traumatic stress disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alto Neuroscience
- 09 May 2024 According to an Alto Neuroscience media release, company announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker based analyses at the Society of Biological Psychiatry (SOBP), to take place May 9 to11 in Austin, TX.
- 07 Dec 2023 According to an Alto Neuroscience media release, data from the trial presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP)
- 07 Dec 2023 Results published in the Alto Neuroscience Media Release